Clinically relevant differences between the statins: Implications for therapeutic selection

被引:140
作者
Chong, PH
Seeger, JD
Franklin, C
机构
[1] Cook Cty Hosp, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL USA
[3] Midwestern Univ, Chicago Coll Pharm, Dept Pharm Practice, Chicago, IL USA
[4] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[5] Finch Univ Hlth Sci, Chicago Med Sch, Chicago, IL USA
关键词
D O I
10.1016/S0002-9343(01)00870-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, share a common lipid-lowering effect, there are differences within this class of drugs. The low-density lipoprotein (LDL) cholesterol-lowering efficacy, pharmacokinetic properties, drug-food interactions, and cost can vary widely, thus influencing the selection of a particular statin as a treatment option. The statins that produce the greatest percentage change in LDL cholesterol levels are atorvastatin and simvastatin. Atorvastatin and fluvastatin are least affected by alterations in renal function. Fewer pharmacokinetic drug interactions are likely to occur with pravastatin and fluvastatin, because they are not metabolized through the cytochrome P450 (3A4) system. The most cost-effective statins, based on cost per percentage change in LDL cholesterol levels, are fluvastatin, cerivastatin, and atorvastatin, Awareness of these differences may assist in the selection or substitution of an appropriate statin for a particular patient. (C) 2001 by Excerpta Medica, Inc.
引用
收藏
页码:390 / 400
页数:11
相关论文
共 100 条
  • [1] Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac
    Agarwal, B
    Rao, CV
    Bhendwal, S
    Ramey, WR
    Shirin, H
    Reddy, BS
    Holt, PR
    [J]. GASTROENTEROLOGY, 1999, 117 (04) : 838 - 847
  • [2] *AM HEART ASS, 2000, 73 SCI SESS AM HEART
  • [3] *AM HEART ASS, 1996, 1997 HEART STROK STA
  • [4] Cost-effectiveness of Pravastatin in secondary prevention of coronary artery disease
    Ashraf, T
    Hay, JW
    Pitt, B
    Wittels, E
    Crouse, J
    Davidson, M
    Furberg, CD
    Radican, L
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (04) : 409 - 414
  • [5] The interaction of diltiazem with lovastatin and pravastatin
    Azie, NE
    Brater, DC
    Becker, PA
    Jones, DR
    Hall, SD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) : 369 - 377
  • [6] Efficacy and tolerability of fluvastatin extended-release delivery system:: A pooled analysis
    Ballantyne, CM
    Pazzucconi, F
    Pintó, X
    Reckless, JP
    Stein, E
    McKenney, J
    Bortolini, M
    Chiang, YT
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (02) : 177 - 192
  • [7] *BAYER CORP, 1999, BAYCOL
  • [8] Berkenboom G, 1998, ACTA CARDIOL, V53, P235
  • [9] Bestehorn HP, 1997, EUR HEART J, V18, P226
  • [10] CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS)
    BLANKENHORN, DH
    AZEN, SP
    KRAMSCH, DM
    MACK, WJ
    CASHINHEMPHILL, L
    HODIS, HN
    DEBOER, LWV
    MAHRER, PR
    MASTELLER, MJ
    VAILAS, LI
    ALAUPOVIC, P
    HIRSCH, LJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) : 969 - 976